With expertise in research, fundraising, policy and more, our staff are dedicated to making breakthroughs possible. Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

There are two main types of Alzheimer’s. Late onset Alzheimer’s starts after age 65, and young onset Alzheimer’s affects people before age 65. Different genes can be involved in the development of the ...